HKUCTR-2807
Untitled Trial
Neoadjuvant Immunotherapy with anti-PD1 in Borderline Resectable Hepatocellular Carcinoma
Dr. Tan-to Cheung·Phase 2·HKU CLINICAL TRIALS REGISTRY·drugRecruiting
Study focus
- Disease/Condition
- Neoplasm
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Dr. Tan-to Cheung
- Funder
- University Grants Committee
- Location
- China
Timeline & enrollment
- Phase
- Phase 2
- Start date
- N/A
- End date
- Dec 13, 2022
ICD-10 classifications
NeoplasmsBenign neoplasmsIn situ neoplasmsPersonal history of other neoplasmsBenign neoplasm: Other specified sites
Data source
- Registry
- HKU CLINICAL TRIALS REGISTRY
- Trial ID
- HKUCTR-2807
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for HKUCTR-2807 through Pure Global AI's free database. This Phase 2 trial is sponsored by Dr. Tan-to Cheung and is currently Recruiting. The study focuses on Neoplasm.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to HKU CLINICAL TRIALS REGISTRY data, helping medical device and pharmaceutical companies navigate clinical research efficiently.